Radiation therapy for advanced neuroendocrine cancers
Part of Cancer clinical trials.
This trial tests a new type of radiation therapy for advanced neuroendocrine cancers that have not responded to standard treatments. It aims to see if this therapy can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have an advanced neuroendocrine cancer that needs treatment and has not responded to, or you cannot have, standard treatments.
- A special scan (MIBG) shows that your cancer cells take up the radioactive tracer.
- You are generally able to care for yourself (ECOG score of 2 or less).
- Your organs (like kidneys, liver, and blood) are working well enough, as shown by blood tests.
- You are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a radioactive medicine called iodine I-131 MIBG to shrink tumors that take up MIBG. It may help people whose neuroblastoma or malignant pheochromocytoma/paraganglioma has come back, progressed, or not responded to standard treatment.
This trial uses a radioactive medicine called 131I-MIBG to treat neuroblastoma or pheochromocytoma that has come back or not responded to standard treatment. The treatment targets and damages cancer cells while trying to spare healthy tissue.
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
This trial provides access to a radioactive medicine called 131I-MIBG for people with certain nerve tumors that have returned or not responded to standard treatment. The treatment targets and kills cancer cells, and it may help when other options have not worked.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
Hear when a new Pheochromocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.